Moreover, we tested responses of these cell lines to the novel targeted B cell receptor (BCR) signaling inhibitors such as ibrutinib and idelalisib, which were initially approved specifically for del(17p)/TP53‐mutated CLL patients. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.